Maravai LifeSciences Holdings, Inc. MRVI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Cygnus | $18.36M+1.4% | $15.27M+4.1% | $16.28M+7.2% | $16.31M+9.9% | $18.1M-0.3% | |
| TriLink | $47.48M+65.1% | $34.6M-17.4% | $25.35M-52.9% | $31.09M-43.1% | $28.75M-37.5% | |
| Cost of revenue by Business | ||||||
| Cygnus | $2.16M-22.8% | —— | —— | —— | $2.8M+13.0% | |
| TriLink | $20.7M-16.6% | —— | —— | —— | $24.82M+4.9% | |
| Adjusted EBITDA for reportable segments by Business | ||||||
| Cygnus | $13.56M+7.0% | —— | —— | —— | $12.67M+15.6% | |
| TriLink | $17.26M+294% | —— | —— | —— | -$8.9M-170% | |
| Sales & Marketing by Business | ||||||
| Cygnus | $789K-4.9% | —— | —— | —— | $830K+13.7% | |
| TriLink | $3.69M-36.0% | —— | —— | —— | $5.77M+11.3% | |
| Other segment items by Business | ||||||
| Cygnus | $1K— | —— | —— | —— | $0-100% | |
| TriLink | $91K+93.6% | —— | —— | —— | $47K+470% | |
| G&A by Business | ||||||
| Cygnus | $1.37M+12.8% | —— | —— | —— | $1.21M+15.6% | |
| TriLink | $3.21M-28.9% | —— | —— | —— | $4.52M-11.3% | |
| Restructuring by Business | ||||||
| Corporate | $743K— | $2.09M— | $3.57M+35,790% | —— | —— | |
| Cygnus | -$3K-122% | $13.5K— | $13.5K— | $13.5K— | $13.5K— | |
| TriLink | $2.14M-38.1% | $3.45M— | $3.45M— | $3.45M— | $3.45M— | |
| Non-Employee Contract Costs by Business | ||||||
| Corporate | $0— | —— | —— | —— | —— | |
| Cygnus | $0— | —— | —— | —— | —— | |
| TriLink | $1.98M— | —— | —— | —— | —— | |
| Other Restructuring Costs by Business | ||||||
| Corporate | $734K— | —— | $167K— | —— | —— | |
| Cygnus | $0-100% | $750— | $750— | $750— | $750— | |
| TriLink | $0-100% | $94.75K— | $94.75K— | $94.75K— | $94.75K— | |
| R&D by Business | ||||||
| Cygnus | $483K-17.4% | —— | —— | —— | $585K+19.4% | |
| TriLink | $2.52M+0.9% | —— | —— | —— | $2.5M+2.9% | |
| Asset Impairments by Business | ||||||
| Corporate | $0-100% | $963.75K— | $963.75K— | $963.75K— | $963.75K— | |
| Cygnus | $0— | $0— | $0— | $0— | $0— | |
| TriLink | $605K-77.6% | $2.7M— | $2.7M— | $2.7M— | $2.7M— | |
| Severance Costs by Business | ||||||
| Corporate | $9K— | —— | $3.42M— | —— | —— | |
| Cygnus | -$3K-124% | $12.75K— | $12.75K— | $12.75K— | $12.75K— | |
| TriLink | -$446K-168% | $655K— | $655K— | $655K— | $655K— | |
| Revenue by Geography | ||||||
| Asia Pacific | $7.87M-25.4% | $14.42M-34.2% | $8.34M-63.6% | $8.16M-65.2% | $10.56M-50.1% | |
| Europe, the Middle East and Africa | $21.95M+219% | $7.68M0.0% | $7.97M-29.9% | $8.4M-38.5% | $6.88M-26.6% | |
| Latin and Central America | $329K+125% | $324K+197% | $296K+137% | $205K+69.4% | $146K-52.4% | |
| North America | $35.69M+21.9% | $27.44M+2.2% | $25.03M-27.7% | $30.64M-5.0% | $29.27M-12.3% | |
| UNITED STATES | $35.2M+22.2% | —— | —— | —— | $28.8M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Maravai LifeSciences Holdings, Inc. break its business down?
- Maravai LifeSciences Holdings, Inc. (MRVI) reports revenue by business across 2 parts — Cygnus and TriLink. Each is extracted from the segment footnotes and tracked over time.
- Where does Maravai LifeSciences Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Maravai LifeSciences Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
